Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 4/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3252218 | 0.83 | CA1 (0.43) | APLNRCA1CA7CA12CA14 | |
| SCHEMBL19362876 | 0.82 | APLNR (0.46) | APLNRCA1CA7CA12CA14 | |
| SCHEMBL3177106 | 0.80 | APLNR (0.44) | APLNRCA1CA7CA12CA14 | |
| SCHEMBL284141 | 0.80 | APLNR (0.55) | APLNRCA1CA7CA12CA14 | |
| SCHEMBL1620621 | 0.79 | HDAC3 (0.46) | APLNRCA1CA7CA12CA14 | |
| SCHEMBL3164804 | 0.78 | APLNR (0.43) | APLNRCA1CA7CA12CA14 | |
| SCHEMBL2087588 | 0.78 | TDP1 (0.52) | APLNRCA1CA7CA12CA14 | |
| SCHEMBL9176308 | 0.78 | CA2 (0.43) | APLNRCA1CA7CA12CA14 | |
| SCHEMBL22816921 | 0.78 | APLNR (0.43) | APLNRCA1CA7CA12CA14 | |
| SCHEMBL1885244 | 0.78 | TDP1 (0.47) | APLNRCA1CA7CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-06-12 | — | — | US | claimed |
| EP-1318142-B1 | T-BUTOXYCARBONYLAMINOETHYLAMINE FOR THE SYNTHESIS OF PNA MONOMER UNITS, AMINO ACID DERIVATIVES, INTERMEDIATES THEREOF, AND PROCESSES FOR PRODUCTIONS OF THEM | CREDIA JAPAN CO LTD (JP) | 2007-04-11 | — | — | EP | claimed |
| US-20050187402-A1 | T-butoxycarbonylaminoethylamine for the synthesis of PNA monomer units, amino acid derivatives, intermediates thereof, and processes for productions of them | CREDIA JAPAN CO., LTD. (JP) | 2005-08-25 | — | — | US | claimed |
| US-20040101839-A1 | Novel functional peptide nucleic acid monomer and process for producing the same | CREDIA JAPAN CO., LTD. (JP) | 2004-05-27 | — | — | US | claimed |
| US-20040039224-A1 | T-butoxycarbonylaminoethylamine for the synthesis of pna monomer units, amino acid derivatives, intermediates thereof, and processes for productions of them | CREDIA JAPAN CO., LTD. (JP) | 2004-02-26 | — | — | US | claimed |
| EP-1357112-A1 | NOVEL FUNCTIONAL PEPTIDE NUCLEIC ACID MONOMER AND PROCESS FOR PRODUCING THE SAME | Applied Biosystems Japan Ltd. (JP) | 2003-10-29 | — | — | EP | claimed |
| EP-1318142-A1 | T-BUTOXYCARBONYLAMINOETHYLAMINE FOR THE SYNTHESIS OF PNA MONOMER UNITS, AMINO ACID DERIVATIVES, INTERMEDIATES THEREOF, AND PROCESSES FOR PRODUCTIONS OF THEM | Applied Biosystems Japan Ltd. (JP) | 2003-06-11 | — | — | EP | claimed |
| US-20240279221-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHROEDINGER INC (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4346815-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Schrödinger, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117715642-A | Heterocyclic compounds and methods of use | 薛定谔公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-110505874-B | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-112624938-B | Novel method for synthesizing ethyl hydrazine dihydrochloride | 南开大学 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022251497-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-0969840-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2001-02-28 | — | — | EP | disclosed |
| EP-0969840-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2000-01-12 | — | — | EP | disclosed |
| US-5932606-A | Pyrazinone, pyridinone, piperidine and pyrrolidine thrombin inhibitors | MERCK & CO., INC. (US) | 1999-08-03 | — | — | US | disclosed |
| US-5902819-A | Triazole derivatives | MERCK SHARP & DOHME LTD. (GB) | 1999-05-11 | — | — | US | disclosed |
| WO-1998042342-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1998-10-01 | — | — | WO | disclosed |
| US-5587478-A | BONDING TO OLIGONUCLEOTIDES, DRUG DELIVERY, THERAPHY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-12-24 | — | — | US | disclosed |
| US-5510362-A | VASOCONSTRUCTION | MERCK, SHARP AND DOHME LIMITED (GB) | 1996-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040101839-A1 | Novel functional peptide nucleic acid monomer and process for producing the same | NSUN3, NSUN2, RNGTT | APLNR 487/4885CA1 2420/4885CA7 2214/4885 |
| US-20050187402-A1 | T-butoxycarbonylaminoethylamine for the synthesis of PNA monomer units, amino acid derivatives, intermediates thereof, and processes for productions of them | BCAT1, BCAT2, RNGTT | APLNR 1866/4885CA1 1059/4885CA7 2159/4885 |
| US-20040039224-A1 | T-butoxycarbonylaminoethylamine for the synthesis of pna monomer units, amino acid derivatives, intermediates thereof, and processes for productions of them | BCAT1, BCAT2, RNGTT | APLNR 2803/4885CA1 648/4885CA7 1254/4885 |
| US-20240279221-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | APC, RCC2, CDC37 | APLNR 3824/4885CA1 2860/4885CA7 1893/4885 |
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | NSUN3, RNGTT, NSUN2 | APLNR 129/4885CA1 3208/4885CA7 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.